Encenicline

Drug Profile

Encenicline

Alternative Names: Alpha-7 nAChR; EVP-6124; MT-4666

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer HealthCare
  • Developer Bayer HealthCare; FORUM Pharmaceuticals; Mitsubishi Tanabe Pharma Corporation
  • Class 2 ring heterocyclic compounds; Amides; Azabicyclo compounds; Nootropics; Quinuclidines; Thiophenes
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease; Cognition disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cognition-disorders in Czech Republic (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cognition-disorders in Hungary (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cognition-disorders in Slovakia (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top